Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a pioneering price
admin 19th December 2017 Uncategorised 0At a time when drugmakers—even rare disease drugmakers—routinely draw fire for their pricing decisions, Spark Therapeutics is surely prepping a pitch for its now-FDA-approved Luxturna. Analysts figure the pioneering therapy’s retail price could break the $1 million barrier.
More: Spark grabs FDA nod for Luxturna, a breakthrough gene therapy likely bearing a pioneering price
Source: fierce